Online citations, reference lists, and bibliographies.
← Back to Search

Pleural Fluid Mesothelin For The Differential Diagnosis Of Exudative Pleural Effusions.

C. Alemán, José Manuel Porcel, Rosa Ma Segura, J. Alegre, A. Esquerda, E. Ruiz, S. Bielsa, T. D. de Sevilla
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Malignant mesothelioma (MM) is a highly aggressive tumor that can be difficult to diagnose, resulting in a delayed diagnosis in some cases. Recent studies have reported that determination of soluble mesothelin-related peptides (SMRP) in pleural fluid may be a promising marker for use in the diagnosis of MM. PATIENTS AND METHODS Pleural fluid SMRP concentration was measured in 68 patients: 47 had malignant pleural effusions (18 MM and 29 metastatic effusion) and 21 had benign pleural effusion (8 infectious disease and 13 idiopathic effusion). Mann-Whitney analysis was used to compare SMRP values according to the etiology of the effusion. RESULTS Pleural fluid SMRP concentration was significantly higher in patients with malignant pleural effusion than in those with benign effusion (P=0.02). When malignant pleural effusions were analyzed separately, MM patients had the highest median pleural fluid SMRP concentration, with significant differences as compared to patients with idiopathic pleural effusion. CONCLUSIONS Soluble mesothelin-related peptide measurement in pleural fluid may aid in the diagnosis of patients presenting with pleural effusion.
This paper references
10.1136/thx.2006.076612
Hunting for a pleural fluid test for mesothelioma: is soluble mesothelin the answer?
Y. Lee (2007)
10.1378/CHEST.07-0013
Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
J. Creaney (2007)
Evolution of Idiopathic Pleural Effusion
JS Ferrer (1996)
10.1016/S0009-9120(00)00157-0
Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies.
C. Fuhrman (2000)
10.1097/00000478-200311000-00003
Application of Mesothelin Immunostaining in Tumor Diagnosis
N. Ordóñez (2003)
10.1158/1078-0432.CCR-04-2304
Humoral Immune Response to Mesothelin in Mesothelioma and Ovarian Cancer Patients
M. Ho (2005)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.1053/J.SEMDP.2006.06.006
Use of mesothelin as a marker for mesothelial cells in cytologic specimens.
Cornelius Kachali (2006)
10.1016/J.LUNGCAN.2005.03.020
Soluble mesothelin-related protein--a blood test for mesothelioma.
B. Robinson (2005)
10.1111/j.1532-5415.2005.00475.x
A Longitudinal Study of Idiopathic Exudative Lymphocytic Pleural Effusion in Older People
A. E. El Solh (2005)
Guidelines of the French Speaking Society for Chest Medicine for management of MM
A. Scherpereel (2007)
Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin.
D. Fan (2002)
10.1016/J.HOC.2005.09.007
Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein.
J. Creaney (2005)
Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).
P. Argani (2001)
10.1158/1078-0432.CCR-07-0629
Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer
A. Cristaudo (2007)
10.1378/CHEST.126.6.1757
Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.
J. M. Porcel (2004)
10.1016/S0025-7753(04)74541-8
Evaluacin diagnstica del derrame pleural
J. M. Porcel (2004)
10.1164/RCCM.200511-1789OC
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
A. Scherpereel (2006)
10.1157/13110211
Importancia de la determinación de la amilasa pleural en los pacientes con derrame neoplásico
M. Haro-Estarriol (2007)
10.1016/J.ATHORACSUR.2007.07.042
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
H. Pass (2008)
10.1634/THEONCOLOGIST.10-7-501
Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature.
D. Shitrit (2005)
10.1378/CHEST.109.6.1508
Evolution of idiopathic pleural effusion: a prospective, long-term follow-up study.
J. Ferrer (1996)
10.1097/00063198-200003000-00013
Mesothelioma: new concepts in diagnosis and management
A. Boylan (2000)
10.1136/thx.2006.068114
Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma
J. Creaney (2007)
10.1056/NEJMCP010731
Clinical practice. Pleural effusion.
R. Light (2002)
Estudio prospectivo de 1000 pacientes consecutivos con derrame pleural. Etiologı́a del derrame pleural y carácterı́sticas de los pacientes
V Villena (2002)
10.1038/sj.bjc.6690807
Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions
M. Miédougé (1999)
Importancia de la determinación de la amilasa pleural en los pacientes con derrame pleural neoplásico
M Haro (2007)
10.1158/1078-0432.CCR-06-2144
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
B. Grigoriu (2007)
10.1097/00132980-200310000-00003
Pleural diseases.
R. Light (1992)
10.1373/CLINCHEM.2006.079327
MESOMARK: a potential test for malignant pleural mesothelioma.
H. L. Beyer (2007)
10.1093/QJMED/HCM032
Differentiating between malignant and idiopathic pleural effusions: the value of diagnostic procedures.
C. Alemán (2007)
10.1007/BF00175946
Value of serum and effusion fluid CEA levels for distinguishing between diffuse malignant mesothelioma and carcinomatous pleural metastases
J. Mezger (2004)
10.1378/CHEST.106.4.1209
The evaluation of pleural effusion.
T. Bartter (1994)
Estudio prospectivo de 1000 pacientes consecutivos con derrame pleural. Etiologı́a del derrame pleural y carácterı́sticas de los pacientes
V Villena (2002)
10.1002/DC.20747
Utility of WT‐1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions
Robert T. Pu (2008)
10.1200/JCO.2003.01.068
Status of tumor markers in ovarian cancer screening.
R. Bast (2003)
10.1016/J.RMED.2006.10.018
Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma.
A. Scherpereel (2007)
Importancia de la determinación de la amilasa pleural en los pacientes con derrame pleural neoplásico
M Haro (2007)
10.1055/b-0034-74110
Pleural effusion.
G. Beaumont (1954)
10.1157/13110211
Original breveImportancia de la determinación de la amilasa pleural en los pacientes con derrame neoplásicoUtility of amylase levels in malignant pleural effusions
M. Haro-Estarriol (2007)
Mesomark TM : A potential test for malignant pleural mesothelioma
H Beyer
10.1016/S0300-2896(02)75142-9
Estudio prospectivo de 1.000 pacientes consecutivos con derrame pleural. Etiología del derrame y características de los pacientes
V. Villena (2002)
Mesothelinfamily protein and diagnosis of mesothelioma
B Robinson (2003)
10.1073/PNAS.96.20.11531
Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.
N. Scholler (1999)
10.1016/S0169-5002(03)00120-X
Diagnostic value of CA 549 in pleural fluid. Comparison with CEA, CA 15.3 and CA 72.4.
V. Villena (2003)
10.1016/S0169-5002(00)00153-7
Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions.
F. Alataş (2001)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)



This paper is referenced by
10.6016/ZDRAVVESTN.2579
Biomarkers in routine diagnosis of pleural effusions
T. Nemanič (2018)
10.1016/j.ccm.2012.11.002
Pleural fluid biomarkers: beyond the Light criteria.
J. M. Porcel (2013)
False positive (18)F-FDG-PET/CT findings in a patient with talc pleurodesis.
S. Sağer (2010)
Malignant pleural mesothelioma : novel biomarkers and related pathways
Filip Mundt (2013)
10.2217/bmm.11.18
Soluble markers for diagnosis of malignant pleural mesothelioma.
A. Cristaudo (2011)
10.1371/journal.pone.0185850
Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center
Takehiro Otoshi (2017)
Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
P. Ferro (2013)
10.3109/07357907.2012.749265
Evaluation of Soluble Mesothelin-related Peptide as a Diagnostic Marker of Malignant Pleural Mesothelioma Effusions: Its Contribution to Cytology
P. Canessa (2013)
10.1007/s13631-012-0047-y
Determinazione della Mesotelina nel versamento pleurico: contributo alla citologia nella diagnosi del Mesotelioma pleurico maligno
E. Battolla (2012)
10.1016/J.MEDCLI.2011.07.008
Derrame pleural tras la cirugía de revascularización mediante derivación aortocoronaria
L. Ferreiro (2012)
10.1136/bmjopen-2013-004145
Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
Ai Cui (2014)
10.1155/2014/413946
Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
J. Creaney (2014)
10.1371/journal.pone.0072030
Hyaluronan and N-ERC/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma
Filip Mundt (2013)
Semantic Scholar Logo Some data provided by SemanticScholar